HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.

[1]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[2]  B. Li,et al.  Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms. , 2004, Virology.

[3]  N. Haigwood.  Predictive value of primate models for AIDS. , 2004, AIDS reviews.

[4]  Christopher J. Miller,et al.  A Period of Transient Viremia and Occult Infection Precedes Persistent Viremia and Antiviral Immune Responses during Multiple Low-Dose Intravaginal Simian Immunodeficiency Virus Inoculations , 2004, Journal of Virology.

[5]  A. McMichael,et al.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques , 1995, Nature Genetics.

[6]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[7]  P. Luciw,et al.  Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. , 2002, Vaccine.

[8]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[9]  L. Grohskopf,et al.  Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. , 2005, The Journal of infectious diseases.

[10]  R. Brookmeyer,et al.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda , 2001, The Lancet.

[11]  P. Kulkarni,et al.  Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. , 2003, AIDS reviews.

[12]  Christopher D Pilcher,et al.  Brief but efficient: acute HIV infection and the sexual transmission of HIV. , 2004, The Journal of infectious diseases.

[13]  V. Maino,et al.  Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. , 1998, Journal of immunology.

[14]  I. Longini,et al.  Preclinical Assessment of HIV Vaccines and Microbicides by Repeated Low-Dose Virus Challenges , 2005, PLoS medicine.

[15]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[16]  Julie Elliott,et al.  Optimization of methods to assess human mucosal T-cell responses to HIV infection. , 2003, Journal of immunological methods.

[17]  Takahiro Hirata,et al.  Cytotoxic T Lymphocyte–based Control of Simian Immunodeficiency Virus Replication in a Preclinical AIDS Vaccine Trial , 2004, The Journal of experimental medicine.

[18]  Christopher D Pilcher,et al.  Amplified HIV transmission and new approaches to HIV prevention. , 2005, The Journal of infectious diseases.

[19]  P. Sen,et al.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.

[20]  C. Rouzioux,et al.  Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. , 1999, AIDS.

[21]  P. Earl,et al.  Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine , 2002, Journal of Virology.

[22]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[23]  Todd M. Allen,et al.  Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.

[24]  R P Johnson,et al.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. , 1998, Science.

[25]  D. Watkins,et al.  Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman Primates , 2004, Journal of Virology.

[26]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[27]  B. Li,et al.  Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. , 2005, Virology.

[28]  T. Greenough,et al.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. , 1997, The Journal of infectious diseases.

[29]  N. Letvin,et al.  Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. , 2000, Developments in biologicals.

[30]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[31]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[32]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[33]  K. Metzner,et al.  Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. , 2000, Virology.

[34]  H. Clifford Lane,et al.  Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.

[35]  Danielle Harvey,et al.  Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV , 2005, Journal of acquired immune deficiency syndromes.

[36]  N. Nathanson,et al.  The role of nonhuman primates in the development of an AIDS vaccine. , 1999, AIDS.

[37]  B. M. Flynn,et al.  Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment , 2001, Journal of Virology.

[38]  D. Montefiori,et al.  Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. , 2001, Immunology letters.

[39]  Todd M. Allen,et al.  Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses , 2003, Journal of Virology.

[40]  R. Kaul,et al.  Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. , 2001, The Journal of clinical investigation.

[41]  D. Watkins,et al.  Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge. , 2002, The Journal of general virology.

[42]  J. Smith,et al.  Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. , 1997, Virology.

[43]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[44]  Todd M. Allen,et al.  Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication , 2002, Journal of Virology.

[45]  M. Ackers,et al.  Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. , 2002, Virology.

[46]  M. Elizabeth Halloran,et al.  A Frailty Mixture Model for Estimating Vaccine Efficacy , 1996 .

[47]  B. Moss,et al.  Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination , 2001, Journal of Virology.